Suicide and awareness of illness in schizophrenia: An overview

Bulletin of the Menninger Clinic

Volumn 68, Issue 4, 2004, Pages 297-318

  Pompili, Maurizio ^a   Ruberto, Amedeo ^a   Kotzalidis, Giorgio D ^a   Girardi, Paolo ^a   Tatarelli, Roberto ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; OLANZAPINE; QUETIAPINE; RISPERIDONE; SERTINDOLE; ZIPRASIDONE;

AWARENESS; CAUSE OF DEATH; COGNITION; HUMAN; REVIEW; RISK FACTOR; SCHIZOPHRENIA; SUICIDE;

CAUSE OF DEATH; HUMANS; RISK FACTORS; SCHIZOPHRENIC PSYCHOLOGY; SELF CONCEPT; SUICIDE;

EID: 12744280720     PISSN: 00259284     EISSN: None     Source Type: Journal    
DOI: 10.1521/bumc.68.4.297.56643     Document Type: Review

References (101)

1. Addington, D., Addington, J., Maticka-Tyndale, E., & Joyce, J. (1992). Reliability and validity of a depression rating scale for schizophrenics. Schizophrenia Research, 6, 201-208.
2. Aguglia, E., De Vanna, M., Onor, M.L., & Ferrara, D. (2002). Insight in persons with schizophrenia: Effects of switching from conventional neuroleptics to atypical antipsychotics. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 26, 1229-1233.
3. Amador, X.F., & David, A.S. (Eds.). (1998). Insight and Psychosis. New York: Oxford University Press.
4. Amador, X.F., Harkavy-Friedman, J., Kasapis, C, Yale, S.A., Flaum, M., & Gorman, J.M. (1996). Suicidal behavior in schizophrenia and its relationship to awareness of illness. American Journal of Psychiatry, 153, 1185-1188.
5. Amador, X.F., Strauss, D.H., Yale, S.A., Flaum, M.M., Endicott, J., & Gorman, J.M. (1993). Assessment of insight in psychosis. American Journal of Psychiatry, 150, 873-879.
6. Amador, X.F., Strauss, D.H., Yale, S.C., & Gorman, J.M. (1991). Awareness of illness in schizophrenia. Schizophrenia Bulletin, 17, 113-132.
7. Andreasen, N.C. (1983). The Scale for the Assessment of Negative Symptoms (SANS). Iowa City, IA: University of Iowa.
8. Andreasen, N.C. (1984). The Scale for the Assessment of Positive Symptoms (SAPS). Iowa City, IA: University of Iowa.
9. Andreasen, N.C., Flaum, M., & Arndt, S. (1992). The Comprehensive Assessment of Symptoms and History (CASH): An instrument for assessing diagnosis and psychopathology. Archives of General Psychiatry, 49, 615-623.
10. Arora, R.C., & Meltzer, H.Y. (1989). Serotonergic measures in the brains of suicide victims: 5-HT2 binding sites in the frontal cortex of suicide victims and control subjects. American Journal of Psychiatry, 146, 730-736.
11. Baechler, J. (1979). Suicide. New York: Basic Books.
12. Bartko, G., Herczeg, I., & Zador, G. (1988). Clinical symptomatology and drug compliance in schizophrenic patients. Acta Psychiatrica Scandinavica, 77, 74-76.
13. Bechdolf, A., Knost, B., Kuntermann, C., Schiller, S., Klosterkotter, J., Hambrecht, M., & Pukrop, R. (2004). A randomized comparison of group cognitive-behavioural therapy and group psychoeducation in patients with schizophrenia. Acta Psychiatrica Scandinavica, 110, 21-28.
14. Benton, A.L., Hamsher, K., Verney, N.R., & Spreen, D. (1983). Contribution to neuropsychological assessment. New York: Oxford University Press.
15. Bourgeois, M., Swendsen, J., Young, F., Amador, X., Pini, S., Cassano, G.B., Lindenmayer, J.P., Hsu, C., Alphs, L., Meltzer, H.Y., & the InterSePT Study Group. (2004). Awareness of disorder and suicide risk in the treatment of schizophrenia: Results of the international suicide prevention trial. American Journal of Psychiatry, 161, 1494-1496.
16. Buschke, H., & Fuld, P.A. (1974). Evaluating storage, retention and retrieval in disordered memory and learning. Neurology, 11, 1019-1025.
17. Caldwell, C.B., & Gottesman, I.I. (1990). Schizophrenics kill themselves too: a review of risk factors for suicide. Schizophrenia Bulletin, 16, 571-589.
18. Carone, B.J., Harrow, M., & Westermeyer, J.F. (1991). Posthospital course and outcome in schizophrenia. Archives of General Psychiatry, 48, 247-253.
19. Cheetham, S.C., Crompton, M.R., Katona, C.L., & Horton, R.W. (1988). Brain 5-HT2 receptor binding sites in depressed suicide victims. Brain Research, 443, 272-280.
20. Cohen, S., Leonard, C.V., Farberow, N.L. & Shneidman, E.S. (1964). Tranquilizers and suicide in the schizophrenic patient. Archives of General Psychiatry, 11, 312-321.
21. Collins, A.A., Remington, G.J., Coulter, K., & Birkett, K. (1997). Insight, neurocognitive function and symptom clusters in chronic schizophrenia. Schizophrenia Research, 27, 37-44.
22. Cotton, P.G., Drake, R.E., & Gates, C. (1985). Critical treatment issues in suicide among schizophrenics. Hospital and Community Psychiatry, 36, 534-536.
23. Cuesta, M.J., Peralta, V., & Zarzuela, A. (2000). Reappraising insight in psychosis. Multi-scale longitudinal study. British Journal of Psychiatry, 177, 233-240.
24. d'Alfonso, A.A.L., Lerman, A., Kessels, R.P.C., Postma, A., van der Linden, J., Cahn, W., Greene, Y., de Haan, E.H.F., & Kahn, R.S. (2002). Transcranial magnetic stimulation of left auditory cortex in patients with schizophrenia: Effects on hallucinations and neurocognition. Journal of Neuropsychiatry and Clinical Neurosciences, 14, 77-79.
25. David, A., Buchanan, A., Reed, A., & Almeida, O. (1992). The assessment of insight in psychosis. British Journal of Psychiatry, 161, 599-602.
26. David, A.S. (1990). Insight and psychosis. British Journal of Psychiatry, 156, 798-808.
27. Dickerson, F.B., Sommerville, J., Origoni, A.E., Ringel, N.B., & Parente, F. (2002). Experiences of stigma among outpatients with schizophrenia. Schizophrenia Bulletin, 28, 143-155.
28. Dittmann, J., & Schuttler, R. (1990). Disease consciousness and coping strategies of patients with schizophrenic psychosis. Acta Psychiatrica Scandinavica, 82, 318-322.
29. Drake, R.E., Gates, C., & Cotton, P.G. (1986). Suicide among schizophrenics: A comparison of attempters and completed suicide. British Journal of Psychiatry, 149, 784-787.
30. Drake, R.E., & Cotton, P.G. (1986). Depression, hopelessness and suicide in chronic schizophrenia. British Journal of Psychiatry, 148, 554-559.
31. Drake, R.E., Gates, C., Cotton, P.G., & Whitaker, A. (1984). Suicide among schizophrenics. Who is at risk. Journal of Nervous and Mental Disease, 172, 613-617.
32. Drake, R.E., & Sederer, L.I. (1986). Inpatient psychosocial treatment of chronic schizophrenia: Negative effects and current guidelines. Hospital and Community Psychiatry, 37, 897-901.
33. Eagles, J.M., Carson, D.P., Begg, A., & Naji, S.A. (2003). Suicide prevention: A study of patients' views. British Journal of Psychiatry, 182, 261-265.
34. Endicott, J., & Spitzer, R.L. (1978). A diagnostic interview: The Schedule for Affective Disorders and Schizophrenia. Archives of General Psychiatry, 35, 837-844.
35. Ertugrul, A. (2002). Clozapine and suicide. American Journal of Psychiatry, 159, 323.
36. Farberow, N.L, Shneidman, E.S., & Leonard, C.V. (1965). Suicide among schizophrenic mental hospital patients. In N.L. Farberow & E.S. Shneidman (Eds.), The cry for help (pp. 78-97). New York: McGraw-Hill.
37. Feinstem, R., & Plutchik, R. (1990). Violence and suicide risk assessment in the psychiatric emergency room. Comprehensive Psychiatry, 31, 337-343.
38. Fenton, W.S. (2000). Depression, suicide, and suicide prevention in schizophrenia. Suicide and Life-Threatening Behavior, 31, 34-49.
39. Fenton, W.S., & McGlashan, T.H. (1991). Natural history of schizophrenia subtypes. Archives of General Psychiatry, 48, 969-977.
40. Fenton, W.S., McGlashan, T.H., Victor, B.J., & Blyler, C.R. (1997). Symptoms, subtype and suicidality in patients with schizophrenia spectrum disorders. American Journal of Psychiatry, 154, 199-204.
41. Greenfeld, D., Strauss, J.S., Bowers, M.B., & Mandelkern, M. (1989). Insight and interpretation of illness in recovery from psychosis. Schizophrenia Bulletin, 15, 245-252.
42. Hamilton, M. (1960). A rating scale for depression. Journal of Neurology, Neurosurgery, and Psychiatry, 23, 56-62.
43. Hankoff, L.D., Engelhardt, D.M., & Freedman, N. (1960). Placebo response in schizophrenic outpatients. Archives of General Psychiatry, 2, 33-42.
44. Harkavy-Friedman, J.M., & Nelson, E. (1997). Management of the suicidal patient with schizophrenia. Psychiatric Clinics of North America, 20, 625-640.
45. Heinrichs, D.W., Cohen, B.P., & Carpenter, W.T. (1985). Early insight and the management of schizophrenic decompensation. Journal of Nervous and Mental Disease, 173, 133-138.
46. Holzinger, A., Löffler, W., Müller, P., Priebe, S., & Angermeyer, M.C. (2002). Subjective illness theory and antipsychotic medication compliance by patients with schizophrenia. Journal of Nervous and Mental Disease, 190, 597-603.
47. Hwu, H.G., Sun, M.C., Chou, T.H., & Chang, M.D. (1987). Community Psychiatric Rating Scale: Reliability and validity study. Chinese Psychiatry ROC, 9, 122-128.
48. Kaplan, J.K., & Harrow, M. (1996). Positive and negative symptoms as risk factors for later suicidal activity in schizophrenics versus depressives. Suicide and Life-Threatening Behavior, 26, 105-121.
49. Kaplan, J.K., & Harrow, M. (1999). Psychosis and functioning as risk factors for later suicidal activity among schizophrenia and schizoaffective patients: A disease-based interactive model. Suicide and Life-Threatening Behavior, 29, 10-24.
50. Kay, S.R., Fiszbein, A., & Opler, L.A. (1987). The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bulletin, 13, 261-276.
51. Keck, P.E., Jr., Strakowski, S.M., & McElroy, S.L. (2000). The efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility, and suicidality in patients with schizophrenia. Journal of Clinical Psychiatry, 63(Suppl 3), 4-9.
52. Kemp, R., & David, A. (1996). Psychological predictors of insight and compliance in psychotic patients. British Journal of Psychiatry, 169, 444-450.
53. Kemp, R., & David, A. (1997). Insight and compliance. In B. Blackwell (Ed.), Compliance and the treatment alliance (chronic mental illness) (pp. 61-84). Amsterdam (NL): OPA (Overseas Publishing Association) Amsterdam B.V.-Harwood Academic Publishers
54. Kemp, R., Kirov, G., Everitt, B., Hayward, P., & David, A. (1998). Randomised controlled trial of compliance therapy. 18-month follow-up. British Journal of Psychiatry, 172, 413-419.
55. Kim, C.H., Jayathilake, K., & Meltzer, H.Y. (2003). Hopelessness, neurocognitive function, and insight in schizophrenia: Relationship to suicidal behavior. Schizophrenia Research, 60, 71-80.
56. Kirkpatrick, B., Buchanan, R.W., Breier, A. & Carpenter, W.T., Jr. (1994). Depressive symptoms and the deficit syndrome of schizophrenia. Journal of Nervous and Mental Disease, 182, 452-455.
57. Langs, R. (1986). Unconscious communication in everyday life. New York: Aronson.
58. Laskowska, D., Urbaniak, K., & Groblewska, K. (1967). Awareness of one's own disease - A motive of suicide in schizophrenia. Psychiatria Polska, 1, 155-157.
59. Linn, E.L. (1965). Relevance of psychotic patients' "insight" to their prognosis. Archives of General Psychiatry, 13, 424-428.
60. Lowther, S., De Paermentier, F., Crompton, M.R., Katona, C.L., & Horton, R.W. (1994). Brain 5-HT2 receptors in suicide victims: Violence of death, depression and effects of antidepressant treatment. Brain Research, 642, 281-289.
61. McEvoy, J.P., Aland, J., Wilson, W.H., Guy, W., & Hawkins, L. (1981). Measuring chronic schizophrenic patients' attitude towards their illness and treatment. Hospital and Community Psychiatry, 32, 856-858.
62. Meltzer, H.Y. (1998). Suicide in schizophrenia: Risk factors and clozapine treatment. Journal of Clinical Psychiatry, 59(supp 3), 15-20.
63. Meltzer, H. (2002). Clozapine and suicide. American Journal of Psychiatry, 159, 323-324.
64. Meltzer, H.Y., & Okayli, G. (1995). Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: Impact on risk-benefit assessment. American Journal of Psychiatry, 152, 183-190.
65. Meltzer, H.Y., Conley, R.R., De Leo, D., Green, A.I., Kane, J.M., Knesevich, M.A., Lieberman, J.A., Lindenmayer, J.P., & Potkin, S.G. (2003). Intervention strategies for suicidality. Journal of Clinical Psychiatry (Audiograph Series) 6, 1-16.
66. Nyman, A.K., & Jonsson, H. (1986). Pattern of self-destructive behavior in schizophrenia. Acta Psychiatrica Scandinavica, 73, 252-262.
67. Overall, J.E. (1974). The Brief Psychiatric Rating Scale in psychopharmacology research. In P. Pichot & R. Olivier-Martin (Eds.), Psychological measurements in psychopharmacology (Modern Problems of Pharmacopsychiatry, Vol. 7, pp. 67-78). Basel, Switzerland: S. Karger Verlag.
68. Overall, J.E., & Gorham, D.R. (1962). The Brief Psychiatric Rating Scale. Psychological Reports, 10, 799-812.
69. Pallanti, S., Quercioli, L., & Pazzagli, A. (1999). Effects of clozapine on awareness of illness and cognition in schizophrenia. Psychiatry Research, 86, 239-249.
70. Pao, P.-N. (1979). Schizophrenic disorders: theory and treatment from a psychodynamic point of view. New York: International Universities Press.
71. Perris, C. (1989). Cognitive therapy with schizophrenic patients. New York: Guilford Press.
72. Peterson, L.R., & Peterson, M.J. (1959). Short-term retention of individual verbal items. Journal of Experimental Psychology, 58, 193-198.
73. Phelan, C., Bromet, E.J., & Link, E.G. (1998). Psychiatric illness and family stigma. Schizophrenia Bulletin, 24, 115-126.
74. Pompili, M., Girardi, P., Ruberto, A., & Tatarelli, R. (2004). Toward a new prevention of suicide in schizophrenia. World Journal of Biological Psychiatry, 5, 201-210.
75. Pompili, M., Mancinelli, I., Girardi, P., & Tatarelli, R. (2003). Preventing suicide in schizophrenia inside family environment. Crisis, 24, 181-182.
76. Pompili, M., Mancinelli, I., & Tatarelli, R. (2002). Schizophrenia, suicide, and blood count during treatment with clozapine. Canadian Journal of Psychiatry, 47, 977.
77. Pompili, M., Mancinelli, I., & Tatarelli, R. (2003). Stigma as a cause of suicide. British Journal of Psychiatry, 183, 173-174.
78. Potkin, S.G., Anand, R., Alphs, L., Fleming, K., & InterSePT Investigators. (2002). Neurocognitive performance does not correlate with suicidality in schizophrenic and schizoaffective patients at risk for suicide. Schizophrenia Research, 59, 59-66.
79. Potkin, S.G., Fleming, K., Jin, Y., & Gulasekaram, B. (2001). Clozapine enhances neurocognition and clinical symptomatology more than standard neuroleptics. Journal of Clinical Psychopharmacology, 21, 479-483.
80. Power, P.J., Bell, R.J., Mills, R., Herrman-Doig, T., Davern, M., Henry, L., Yuen, H.P., Khademy-Deljo, A., & McGorry, P.D. (2003). Suicide prevention in first episode psychosis: The development of a randomised controlled trial of cognitive therapy for acutely suicidal patients with early psychosis. Australian and New Zealand Journal of Psychiatry, 37, 414-420.
81. Saarinen, P.I., Lehtonen, J. & Lonnqvist J. (1999). Suicide risk in schizophrenia: An analysis of 17 consecutive suicides. Schizophrenia Bulletin, 25, 533-542.
82. Schwartz, R.C. (2000). Insight and suicidality in schizophrenia: A replication study. Journal of Nervous and Mental Disease, 188, 235-237.
83. Schwartz, R.C., & Petersen, S. (1999). The relationship between insight and suicidality among patients with schizophrenia. Journal of Nervous and Mental Disease, 187, 376-378.
84. Selten, J.P., Gernaat, H., Nolen, W.A., Wiersman, D., & van der Bosch, R.J. (1998). Experience of negative symptoms: Comparison of schizophrenic patients with depressive disorder and to normal subjects. American Journal of Psychiatry, 155, 350-354.
85. Sernyak, M.J., Desai, R., Stolar, M., & Rosenheck, R. (2001). Impact of clozapine on completed suicide. American Journal of Psychiatry, 158, 931-937.
86. Singer, R.G., & Blumenthal, I.J. (1969). Suicide clues in psychotic patients. Mental Hygiene, 53, 346-350.
87. Spiebl, H., Hübner-Liebermann, B., & Cording, C. (2002). Suicidal behaviour of psychiatric in-patients. Acta Psychiatrica Scandinavica, 106, 134-138.
88. Steblaj, A., Tavcar, R., & Dernovsek, M.Z. (1999). Predictors of suicide in psychiatric hospital. Acta Psychiatrica Scandinavica, 100, 383-388.
89. Talland, G.A. (1965). Deranged memory. New York: Academic Press.
90. Tamam, L., & Özpoyraz, N. (2001). Suicide during clozapine treatment: A case report. Israel Journal of Psychiatry and Related Sciences, 38, 127-132.
91. Townsend, J.M. (1975). Cultural conception and mental illness: A controlled comparison of Germany and America. Journal of Nervous and Mental Disease, 160, 409-421.
92. Turkington, D., Kingdon, D., & Turner, T., for the Insight into Schizophrenia Research Group. (2002). Effectiveness of a brief cognitive-behavioural therapy intervention in the treatment of schizophrenia. British Journal of Psychiatry, 180, 523-527.
93. 2a receptor binding index, hopelessness and personality characteristics in attempted suicide. Journal of Affective Disorders, 74, 149-58.
94. Van Putten, Y., Crompton, E., & Yale, C. (1976). Drug refusal in schizophrenia and the wish to be crazy. Archives of General Psychiatry, 33, 1443-1446.
95. Virkkunen, M. (1976). Attitude to psychiatric treatment before suicide in schizophrenia and paranoid psychosis. British Journal of Psychiatry, 128, 47-49.
96. Ward, J.C., & Dow, M.G. (1994). Structured Clinical Interview for the Functional Assessment Rating Scale. Tampa, FL: University of South Florida, Department of Community Mental Health.
97. Warnes, H. (1968). Suicide in schizophrenia. Diseases of the Nervous System, 29, 35-40.
98. Wechsler, D. (1974). WAIS-R Manual. Wechsler Intelligence Scale for Children-Revised. New York: Psychological Corporation.
99. Wechsler, D. (1981). WAIS-R Manual. Wechsler Adult Intelligence Scale-Revised. New York: Psychological Corporation.
100. Westermeyer, J.F., Harrow, M., & Marengo, J.T. (1991). Risk for suicide in schizophrenia and other psychotic and nonpsychotic disorders. Journal of Nervous and Mental Disease, 179, 259-266.
101. Yen, C.F., Yeh, M.L., Chen, C.S., & Chung, H.H. (2002). Predictive value of insight for suicide, violence, hospitalization, and social adjustment for outpatients with schizophrenia: A prospective study. Comprehensive Psychiatry, 43, 443-447.